辽宁成大生物股份有限公司关于韶关市高腾企业管理有限公司要约收购公司股份交割完成的公告

Core Viewpoint - The announcement details the completion of the share acquisition by Shaoguan Gaoteng Enterprise Management Co., Ltd. of Chengda Biological, with a total of 6,939 shares acquired, representing 0.0017% of the company's total share capital [1][2]. Group 1 - Shaoguan Gaoteng made a public offer to acquire 183,971,587 shares of Chengda Biological, which is 44.18% of the total share capital, at a price of 25.51 yuan per share [1]. - The offer period for the acquisition was from March 5, 2025, to April 3, 2025 [1]. - As of the end of the offer period, only 19 shareholders accepted the offer, resulting in a total of 6,939 shares being acquired [2]. Group 2 - The acquisition procedures have been completed, and Shaoguan Gaoteng now holds 6,939 shares, maintaining compliance with the listing conditions of the Shanghai Stock Exchange [2]. - The company's listing status remains unaffected by this acquisition [2].